165 related articles for article (PubMed ID: 22190871)
1. Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer.
Ortega-Cava CF; Raja SM; Laiq Z; Bailey TA; Luan H; Mohapatra B; Williams SH; Ericsson AC; Goswami R; Dimri M; Duan L; Band V; Naramura M; Band H
J Carcinog; 2011; 10():29. PubMed ID: 22190871
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
3. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
4. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
5. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
[TBL] [Abstract][Full Text] [Related]
6. Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis.
Deng X; Li Q; Hoff J; Novak M; Yang H; Jin H; Erfani SF; Sharma C; Zhou P; Rabinovitz I; Sonnenberg A; Yi Y; Zhou P; Stipp CS; Kaetzel DM; Hemler ME; Yang XH
Neoplasia; 2012 Aug; 14(8):678-89. PubMed ID: 22952421
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of eIF2alpha dephosphorylation inhibits ErbB2-induced deregulation of mammary acinar morphogenesis.
Sequeira SJ; Wen HC; Avivar-Valderas A; Farias EF; Aguirre-Ghiso JA
BMC Cell Biol; 2009 Sep; 10():64. PubMed ID: 19754954
[TBL] [Abstract][Full Text] [Related]
8. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.
Lam PB; Burga LN; Wu BP; Hofstatter EW; Lu KP; Wulf GM
Mol Cancer; 2008 Dec; 7():91. PubMed ID: 19077306
[TBL] [Abstract][Full Text] [Related]
9. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
10. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation.
Raven JF; Williams V; Wang S; Tremblay ML; Muller WJ; Durbin JE; Koromilas AE
Cell Cycle; 2011 Mar; 10(5):794-804. PubMed ID: 21311224
[TBL] [Abstract][Full Text] [Related]
11. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Chu I; Blackwell K; Chen S; Slingerland J
Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
[TBL] [Abstract][Full Text] [Related]
12. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.
Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM
Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284
[TBL] [Abstract][Full Text] [Related]
13. ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth.
Khan IA; Yoo BH; McPhee M; Masson O; Surette A; Dakin-Hache K; Younis T; Bethune G; Rosen KV
Breast Cancer Res; 2018 Dec; 20(1):151. PubMed ID: 30545388
[TBL] [Abstract][Full Text] [Related]
14. Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation.
Yu M; Lin G; Arshadi N; Kalatskaya I; Xue B; Haider S; Nguyen F; Boutros PC; Elson A; Muthuswamy LB; Tonks NK; Muthuswamy SK
Mol Cell Biol; 2012 Oct; 32(19):3913-24. PubMed ID: 22851698
[TBL] [Abstract][Full Text] [Related]
15. ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.
Kedrin D; Wyckoff J; Boimel PJ; Coniglio SJ; Hynes NE; Arteaga CL; Segall JE
Clin Cancer Res; 2009 Jun; 15(11):3733-9. PubMed ID: 19458057
[TBL] [Abstract][Full Text] [Related]
16. Brk is coamplified with ErbB2 to promote proliferation in breast cancer.
Xiang B; Chatti K; Qiu H; Lakshmi B; Krasnitz A; Hicks J; Yu M; Miller WT; Muthuswamy SK
Proc Natl Acad Sci U S A; 2008 Aug; 105(34):12463-8. PubMed ID: 18719096
[TBL] [Abstract][Full Text] [Related]
17. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.
Arias-Romero LE; Villamar-Cruz O; Pacheco A; Kosoff R; Huang M; Muthuswamy SK; Chernoff J
Oncogene; 2010 Oct; 29(43):5839-49. PubMed ID: 20711231
[TBL] [Abstract][Full Text] [Related]
18. Heat shock factor Hsf1 cooperates with ErbB2 (Her2/Neu) protein to promote mammary tumorigenesis and metastasis.
Xi C; Hu Y; Buckhaults P; Moskophidis D; Mivechi NF
J Biol Chem; 2012 Oct; 287(42):35646-35657. PubMed ID: 22847003
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
[TBL] [Abstract][Full Text] [Related]
20. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
Zhan L; Xiang B; Muthuswamy SK
Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
